Isis Shows Targeting miRNA with Antisense Benefits Obese Mice; More Work Remains Before the Clinic | GenomeWeb

Isis Pharmaceuticals this week released preclinical data from its microRNA drug-discovery program showing that antisense-based inhibition of miR-122 improved the health of obese mice without significant side effects.

While the findings support further development of drugs targeting miR-122, Isis Senior Vice President of Research Frank Bennett noted that the science of microRNAs is still new, and that additional research is needed to fully elucidate their role before clinical trials could proceed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.